Paclitaxel Formulation Solubilization Without Cremophor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of hydrophobic agents like paclitaxel face challenges due to insolubility in aqueous solutions and adverse reactions caused by excipients such as Cremophor, leading to high side effects and complex manufacturing processes.
Innovation Solution
Development of a composition comprising paclitaxel or its analogs conjugated with a polypeptide vector, using solubilizing agents like Solutol HS 15 and DMSO, and buffering agents to create a stable, Cremophor-free formulation that can be lyophilized and reconstituted for administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Cremophor is used as a solubilizing agent in paclitaxel formulations, then paclitaxel solubility is improved, but hypersensitivity reactions and side effects increase
Solution Approach 1:
The invention extracts and removes Cremophor EL from the paclitaxel formulation system. By developing alternative Cremophor-free formulations using excipients like Solutol HS 15, polysorbate 80, or polysorbate 20, the patent eliminates the harmful Cremophor component while maintaining paclitaxel solubility through other solubilizing agents, thereby resolving the hypersensitivity issue
Solution Approach 2:
The invention introduces intermediary substances to replace Cremophor's solubilizing function. These intermediaries include alternative excipients such as Solutol HS 15, polysorbate 80, and polysorbate 20, which serve as mediating agents to solubilize paclitaxel without causing the adverse hypersensitivity reactions associated with Cremophor
2Object-affected harmful factors
If paclitaxel is administered over 4 hours to minimize hypersensitivity effects, then side effects are reduced, but administration time increases
Solution Approach 1:
The invention applies preliminary action by removing the harmful Cremophor component before administration. By formulating paclitaxel without Cremophor from the outset, the need for prolonged 4-hour infusion to mitigate hypersensitivity is eliminated, allowing for faster administration while maintaining safety
Solution Approach 2:
The invention converts the harmful effect of Cremophor-induced hypersensitivity into a benefit by developing Cremophor-free formulations. This transformation allows for rapid administration (converting the time loss from long infusions into time gain) while eliminating the hypersensitivity risk, thus turning the original problem into an advantage
3Quantity of substance
If paclitaxel is solubilized in non-aqueous or surfactant buffers, then solubility is improved, but manufacturing complexity and side effects increase
Solution Approach 1:
The invention applies parameter changes by modifying the excipient composition parameters in the formulation. By changing from Cremophor-based systems to alternative surfactant systems (Solutol HS 15, polysorbate 80, polysorbate 20) and optimizing their concentrations, the patent achieves paclitaxel solubility with simplified, more manageable manufacturing processes and reduced side effect profiles
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation enhances the solubility and stability of paclitaxel, reduces side effects, and allows for more rapid and frequent administration without the need for premedication, maintaining therapeutic efficacy while minimizing adverse reactions.
Implementation Method 1
using solubilizing agents like Solutol HS 15
Implementation Method 2
using solubilizing agents like Solutol HS 15 and DMSO
Implementation Method 3
a buffering agent (e.g., glycine, lactic acid, or citric acid, or any buffering agent described herein)... where the buffering agent maintains the solution at a pH of less than 6
Implementation Method 4
allows for more rapid and frequent administration... The composition may be dissolved in water
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Pharmaceutical compositions useful for hydrophobic agents paclitaxel, paclitaxel analogs and conjugates thereof (e g ANG1005) which do not contain Cremophor The compositions further comprise an optional tonicity agent, a buffering agent a bulking agent and a solubilizmg agent which is not Cremophor Methods of preparing said compositions and of said compositions in the treatment of cancer are also included.